Law and Regulations

A Q&A with Douglas Hoey, CEO of NCPA, on how the new provision from CMS requiring DIR fees at the point of sale is impacting independent pharmacies in 2024.

See what's trending in pharmacy with a preview of the Total Pharmacy April issue.

This week, a divided America watched as the Supreme Court heard oral arguments regarding whether to reinstate restrictions on accessing mifepristone, an essential drug used in medication abortion.

As pharmacy benefit managers gain leverage to continue driving up drug prices, local pharmacies struggle to keep up and Congress has been called to act—but it might be too late.

Health care professionals, industry leaders, and politicians gathered for a virtual roundtable to discuss the state of the PBM industry.

The decision comes a year after a group of conservative attorneys generals threatened the chains with legal action.

How much longer can independent pharmacists survive with the current method of reimbursement?

The Congressional Budget Office last year estimated that price negotiation will lower average drug prices in Medicare and will reduce the budget deficit by $25 billion in 2031, including lowering Part D spending by $14 billion and Part B spending by $9 billion. Other federal spending will be lowered by $1 billion.

The Equitable Community Access to Pharmacist Services Act seeks to ensure that seniors in rural and underserved communities have access to care and services from pharmacists for common infectious diseases.

Just weeks after it gained FDA approval, pharmacy organizations have come forward to voice concerns about the safety and security of Florida’s drug importation program.

In August, the FDA issued a 1-year stabilization policy on the final enhanced drug distribution security requirements under the DSCSA. What exactly does that mean for pharmacists?

By importing drugs in bulk from Canada, Florida aims to relieve the financial strain faced by patients who struggle to afford necessary medications.

No major pharmacy chains across the United States require a warrant to release sensitive prescription data, including data regarding birth control or mental health conditions, with law enforcement agencies.

Speakers at AMCP Nexus 2023 provided an in-depth understanding of how changes brought on by the Inflation Reduction Act (IRA) have impacted Medicare, as well as what provisions are to come.

Panelists at AMCP Nexus 2023 provided a rundown of the 340B discount program and addressed whether it's actually working to lower out-of-pocket costs for patients.

An ounce of prevention is well worth a pound of cure when it comes to DEA investigations.

Tiffany Capps, CPhT, pharmacy operations manager at Galloway-Sands Pharmacy in North Carolina and marketing communications manager at CPESN, discusses how med sync programs can help boost a pharmacy's bottom line.

Over the last two legislative sessions, many bills have been introduced in the both the House and the Senate, but there are four bills that are important to watch.

The new deadline to be in compliance with the requirements will be November 27, 2024.

A Q&A with Matt Sample, senior vice president of manufacturer and replenishment operations at AmerisourceBergen.

Illinois Governor JB Pritzker signed into a law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.

The Equitable Community Access to Pharmacy Services legislation was introduced earlier this year in the House of Representatives.

Filling a prescription for a controlled substance requires more oversight than the average prescription.

Despite the increase in drug costs outpacing inflation, Pennsylvania seniors are still paying the same amount for prescriptions that they did in 1990.

NCPA, NACDS, and APhA have joined the Healthcare Distribution Alliance in calling for a delay in the implementation of DSCSA.

The Drug Supply Chain Security Act has been a decade in the making. Pharmacists must be prepared to comply by November 2023.

Three new bills signed Monday will require PBMs to use prescription drug rebates to lower premiums and out-of-pocket costs for consumers and prevent the practice of spread pricing.